Frostbite and Iloprost or Similar

Bello, J. W., Rickrode, G. A., Harlan, N. P., & Buckey, J. C. (2023). Systemic prostacyclin analogues for frostbite require careful monitoring. Journal of Burn Care & Research, 44(2), 487–488.

Bixio, R., Adami, G., Bertoldo, E., Giollo, A., Morciano, A., Bertelle, D., Orsolini, G., Idolazzi, L., Rossini, M., & Viapiana, O. (2022). Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis. Therapeutic Advances in Musculoskeletal Disease, 14, 1759720X221137125.

Cauchy, E., Cheguillaume, B., & Chetaille, E. (2011). A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. New England Journal of Medicine, 364(2), 189–190.

Eslami, A., & Lauver, B. (n.d.). Utilization of epoprostenol in the management of severe frostbite. Chest. (Conference abstract—no DOI available)

Gauthier, J., Morris-Janzen, D., & Poole, A. (2023). Iloprost for the treatment of frostbite: A scoping review. International Journal of Circumpolar Health, 82(1), 2189552.

Khan, S., Mooncai, T., & Sandhu, S. (n.d.). Thawing the system: Frostbite treated with epoprostenol. Chest. (Conference abstract)

Law, S. T., Farber, H. W., & Simms, R. W. (2017). Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases. Journal of Scleroderma and Related Disorders, 2(3), 208–212.

Poole, A., & Gauthier, J. (2016). Treatment of severe frostbite with iloprost in northern Canada. CMAJ, 188(17–18), 1255–1258.